Elsevier

Vaccine

Volume 20, Issues 5–6, 12 December 2001, Pages 943-948
Vaccine

A candidate phocid herpesvirus vaccine that provides protection against feline herpesvirus infection

https://doi.org/10.1016/S0264-410X(01)00378-4Get rights and content

Abstract

Phocid herpesvirus type 1 (PhHV-1) causes significant morbidity and mortality among young and immunocompromised harbour seals. Therefore, the availability of an effective PhHV-1 vaccine would be of importance for orphanages and seal rehabilitation centres. Since possibilities to test PhHV-1 candidate vaccines in the target species are limited, a suitable animal model is needed. Given the close genetic and antigenic relationships between PhHV-1 and feline herpesvirus (FHV), the FHV cat system could be considered to test candidate PhHV-1 vaccines. Here we have tested a PhHV-1 based ISCOM vaccine for its protective efficacy against FHV infection in cats. To this end, three groups of cats were vaccinated thrice with ISCOM adjuvanted PhHV-1, FHV, and mock vaccines, respectively. One month after the last vaccination, all cats were challenged with a virulent FHV strain. All PhHV-1 and FHV vaccinated cats were protected from developing severe disease and excreted significantly less FHV than the mock vaccinated cats.

Introduction

To date, two herpesviruses in seals have been identified: (1) phocid herpesvirus type 1 (PhHV-1), an alpha-herpesvirus; and (2) phocid herpesvirus type 2, a tentative gamma-herpesvirus [1], [2]. Like other alpha-herpesvirus infections, PhHV-1 causes disease in its target species, ranging from severe generalised fatal disease in pups to a mild self-limiting upper respiratory tract disease in otherwise healthy adult seals [3]. Outbreaks of PhHV-1 infections are a severe management problem in seal orphanages and rehabilitation centres, and currently no PhHV-1 vaccine is available. Virus vaccines that are used in wild animals or animals that have to be re-introduced in the wild should as a matter of principle not be based on replication competent live attenuated viruses. Therefore, inactivated or subunit vaccines would be preferred. Since vaccines against herpesvirus infections should probably induce adequate T-cell responses, inducing MHC class I restricted cytotoxic T-lymphocyte (CTL) responses, which is usually not achieved by non-replicating vaccines, adjuvants should be used that would allow the induction of adequate T-cell responses with non-replicating antigens. Therefore, in the current study we have chosen to use the presentation of PhHV-1 antigens in ISCOM (for review see [4]). For obvious reasons, possibilities to test candidate vaccines in seals are limited. Given the antigenic and genetic relationship between PhHV-1 and feline herpesvirus (FHV) [1], [2], [5], the FHV–cat system could be considered for the preliminary testing of candidate PhHV-1 vaccines. Here we have tested the efficacy and safety of a candidate PhHV-1 based ISCOM vaccine together with candidate FHV and as a control canine distemper virus (CDV) based ISCOM vaccines prepared in the same way, in the FHV cat system.

Section snippets

Virus preparations

Crandell feline kidney cells (CrFK) and Vero cells were seeded into roller bottles at a concentration of 2.5×106 cells per 100 ml Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2% penicillin–streptomycin and 5% fetal bovine serum. Once monolayers were formed, CrFK cells were infected at a multiplicity of infection (moi) of approximately 10−4 of either FHV (strain 6887/Han90) [5] or PhHV-1 (strain PB84) [4]. Vero cells were infected with CDV (Bussel strain) at a moi of approximately

Response to vaccination

After each of the three vaccinations with the respective vaccines, the animals were monitored for apparent clinical side effects of vaccination. In none of the animals side effects were observed.

Sera were tested for their ability to neutralise FHV in the presence of 4% (v/v) rabbit serum. The cats in the PhHV-1 ISCOM vaccinated group developed lower levels of cross-neutralising antibodies against FHV than the cats in the FHV ISCOM vaccinated group. Mean antibody responses after vaccinations and

Discussion

In the present paper we have shown that a PhHV-1 based ISCOM vaccine is safe and induces partial cross-protection from FHV disease in cats to a similar extent as an ISCOM based on FHV candidate vaccine. Therefore, we may expect that the tested PhHV-1 vaccine will offer significant protection to PhHV-1 induced disease in seals.

The PhHV-1 ISCOM was effective, as cats of the PhHV-1 ISCOM vaccinated group were protected against development of severe clinical symptoms as measured by the absence of

Acknowledgements

We thank Thijs Kuiken for carefully reviewing the manuscript and Marco van de Bildt for technical assistance.

References (16)

There are more references available in the full text version of this article.

Cited by (8)

  • Unity and diversity among viral kinases

    2020, Gene
    Citation Excerpt :

    It is interesting to observe that grouping into clades is host-specific, i.e., the viruses that infects fishes, birds, and higher organisms formed three distinct clades. Feline herpesvirus and Phocid herpesvirus that infects Cat and Seal respectively are closely related (Martina et al., 2001) and the kinases belonging to these two viruses formed a single clade. In a similar way, the kinases encoded in Psittacid virus that causes Pacheco’s disease in parrots (Thureen and Keeler, 2006) and infectious laryngotracheitis virus that infects chickens formed a unique clade.

  • In vitro assessment of the feline cell-mediated immune response against feline panleukopeniavirus, calicivirus and felid herpesvirus 1 using 5-bromo-2'-deoxyuridine labeling

    2012, Veterinary Immunology and Immunopathology
    Citation Excerpt :

    Although this is a promising inactivation method that has been used frequently because it mainly targets the genome, there have been reports of structural modifications of viral proteins which can have an influence on the immunogenic capacities of the inactivated virus (Miller and Plageman, 1974). Another group found significant proliferation signals in response to FeHV-1 antigens, however, their method of vaccination and restimulation, using immune stimulating complexes and purified virus protein differed significantly from our method (Martina et al., 2001). In addition, their in vitro restimulation assay involved adding exogenous IL-2 to the incubation medium which could modify the response, especially since, in a normal response, activated lymphocytes produce their own IL-2 and thus stimulate their own proliferation.

View all citing articles on Scopus
View full text